Back to results
US 2023/0416364 A1Published application
Methods of redirecting of il-2 to target cells of interest
AssigneeBristol-Myers Squibb Company
InventorsFlavio SCHWARZ, Xiaodi DENG, Pavel STROP
Life of this patent
Estimating the term…
Abstract
The present disclosure provides constructs comprising an anti-PDI antibody, or an alternative targeting moiety, fused to CD25 or an IL-2 binding fragment of CD25. Such constructs find use in treating human diseases, such as cancer.
Claims32
A polypeptide construct comprising a targeting moiety and a CD25 moiety, each of which comprises one or more amino acid sequences.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.